Endometriosis is a chronic gynaecologic condition affecting up to one in every 10 women. KK Women’s and Children’s Hospital (KKH) in Singapore treats approximately 1,200 women with endometriosis-related problems every year. Audrey Abella speaks with Dr Wei-Wei Wee-Stekly, consultant at the Minimally Invasive Surgery Unit at KKH, on how this condition can be appropriately addressed in the primary care setting.
Adding ribociclib, a CDK*4/6 inhibitor, to NSAI** and goserelin improves progression-free survival (PFS) in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), according to the MONALEESA-7*** study presented at ESMO Asia 2018.
Rapid blood pressure (BP) elevations during the second trimester of pregnancy may pose an increased risk of delivering a low birthweight (LBW) infant, as well as contribute to impaired maternal liver, kidney and coagulation functions, according to a study presented at the 2018 American Heart Association (AHA) Scientific Sessions in Chicago, Illinois, US.
Cancer of the corpus uteri (uterine cancer) accounted for nearly 7 percent of all female cancers in Singapore between 2011 and 2015 and was the fourth most frequent female cancer among all Singaporeans.The majority of patients are diagnosed with cancer confined to the uterus and have a 5-year survival rate exceeding 90 percent, while the survival rate of stage IV endometrial cancer is approximately 20 percent. This highlights the importance of recognizing and detecting endometrial cancers early in the natural history.
Minimally invasive radical hysterectomy is associated with poorer survival than open surgery in patients with early-stage cervical cancer, data from two large US databases and a randomized trial have shown.
Treatment with the PD-L1 inhibitor atezolizumab on top of standard chemotherapy with nab-paclitaxel significantly improves progression-free survival (PFS) in triple-negative breast cancer (TNBC) compared with nab-paclitaxel alone, top-line results from the IMpassion* 130 trial reveal. In particular, median overall survival (OS) was 10 months longer with atezolizumab among PD-L1-positive (PD-L1+) patients in an interim analysis.
New drug applications approved by US FDA as of 16 - 31 October 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Adding the combination therapy of zoledronic acid + letrozole to triptorelin as adjuvant treatment for hormone receptor positive (HR+) early breast cancer in premenopausal women significantly improves disease-free survival (DFS) compared with the combination of tamoxifen and triptorelin, according to the HOBOE-2* study presented at ESMO 2018.
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.